II. Correction of Errors

In FR Doc. 2016–27424 of November 15, 2016 (81 FR 80078), there was a technical error in the table that appeared in the notice that is identified and corrected in the Correction of Errors section below.

II. Correction of Errors

In FR Doc. 2016–27424 of November 15, 2016 (81 FR 80078), make the following correction:

On page 80080, in Table 1 entitled, Federal Medical Assistance Percentages and Enhanced Federal Medicaid Assistance Percentages, Effective October 1, 2017–September 30, 2018—Continued”, change the third column entitled, “Enhanced federal medical assistance percentages” for Utah from 78.18 to 79.18.

Dated: November 30, 2016.

Madhura C. Valverde,
Executive Secretary, Department of Health and Human Services.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging: Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council on Aging.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Aging.
Date: January 17–18, 2017.
Closed: January 17, 2017, 3:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 31, C Wing 6th Floor Conference Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

Open: January 17, 2017. 8:00 a.m. to 1:15 p.m.

Agenda: Call to order and report from the Director; Discussion of future meeting dates; Consideration of minutes of last meeting; Reports from Task Force on Minority Aging Research, Working Group on Program, and Program Highlights; Council Speaker; and Intramural Program Report.

Place: National Institutes of Health, Building 31, C Wing 6th Floor Conference Room 10, 9000 Rockville Pike, Bethesda, MD 20892.
Closed: January 18, 2017, 1:15 p.m. to 1:45 p.m.

Agenda: To review and evaluate Intramural Research Program.

Place: National Institutes of Health, Building 31, C Wing 6th Floor Conference Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Robin Barr, Director, National Institute on Aging, Office of Extramural Activities, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20814, (301) 496–9022, barr@nia.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit.

Information is also available on the Institute’s/Center’s home page: www.nih.gov/nia/naca/, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866. Aging Research, National Institutes of Health, HH5)

Dated: November 30, 2016.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.


Date: January 12, 2017.
Time: 1:05 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Cathy J. Weeden, Ph.D., Scientific Review Officer, Division of
Lipid Efflux From Cells for Treatment of Vascular Disorders

Description of Technology: This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, aortic valve stenosis, atherosclerosis, carotid atherosclerosis, congestive heart failure, cerebral stroke, coronary artery disease, inflammation of the cardiovascular system, intermittent claudication, myocardial infarction, peripheral vascular disease, postischemic reperfusion, renal artery stenosis, reperfusion myocardial injury, restenosis, and thrombotic stroke.

Potential Commercial Applications:
- Treatment and prevention of many hereditary, chronic and acute dyslipidemic and vascular disorders, where other treatments are not effective or too invasive, such as statins, partial ileal bypass surgery, portacaval shunt, liver transplantation, and removal of atherogenic lipoproteins by one of several apheresis procedures.
- Also applicable to the treatment of inflammation, asthma, colitis, inflammatory bowel disease (IBD), chronic kidney disease (CKD).

Development Stage: Early-stage; In vitro data available; In vivo data available (animal)

Inventors: Alan T. Remaley, Stephen J. Demosky, John A. Stonik, Marcelo J.A. Amar, Edward B. Neufeld, Fairwell Thomas, H. Bryan Brewer (all of NHLBI)

Publications:
7. Dal C, et al. Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-